Ascendis Pharma A/S

Ascendis Pharma A/S Debt

The Debt of Ascendis Pharma A/S (ASND) as of Nov 20, 2026 is 871.41 M EUR. In the previous year, Debt was 856.62 M EUR — a change of 1.73% (higher).

Debt

871.41 MEUR

YoY

1.73%

Last updated:

In 2025, Ascendis Pharma A/S's total debt was 871.41 M EUR, a 1.73% change from the 856.62 M EUR total debt recorded in the previous year.

The Ascendis Pharma A/S Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
0.00 EUR
Jan 1, 2019
36.62 M EUR
Jan 1, 2020
91.98 M EUR
Jan 1, 2021
209.92 M EUR
Jan 1, 2022
617.57 M EUR
Jan 1, 2023
743.06 M EUR
Jan 1, 2024
856.62 M EUR
Jan 1, 2025
871.41 M EUR
The Ascendis Pharma A/S Debt history
YEARDebtYoY
871.41 MEUR+1.73%
856.62 MEUR+15.28%
743.06 MEUR+20.32%
617.57 MEUR+194.19%
209.92 MEUR+128.24%
91.98 MEUR+151.17%
36.62 MEUR—
0.00EUR—
0.00EUR—
0.00EUR—
0.00EUR—
0.00EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ascendis Pharma A/S Stock analysis

What does Ascendis Pharma A/S do? Ascendis Pharma A/S is a biopharmaceutical company based in Denmark that focuses on developing innovative therapies for diseases that currently have no suitable treatment options. The company was founded in 2007 and is headquartered in Hellerup, Denmark. History The company was founded by an experienced team of researchers and professionals from the pharmaceutical and biotech industry who recognized the need for new therapies for chronic diseases. They used innovative technologies to develop drugs that would have longer-lasting effects, thus reducing the need for frequent doses. In 2015, the company went public to raise additional capital for the further development of their technologies and products. Business model Ascendis Pharma A/S is working on the development of drugs using a proprietary technology platform called TransCon technology. TransCon technology is a novel delivery system that allows drugs to remain in the body for longer periods of time, thus achieving a continuous effect. This leads to a reduced need for frequent doses, improving patient care and adherence to therapy. The company follows an asset-based business model strategy. It aims to market its products globally through a licensing and partnering approach. By partnering with established pharmaceutical companies, Ascendis Pharma A/S can introduce their drugs into broader markets while ensuring resources for further research and development. Divisions Ascendis Pharma A/S has two main business divisions: 1. Endocrinology: Ascendis Pharma A/S is a leader in the development of therapies for diseases caused by hormonal disorders. The TransCon technology is used for the delivery of hormones such as growth hormone, parathyroid hormone, follicle-stimulating hormone, and luteinizing hormone to achieve continuous release in the body. 2. Oncology: The company also utilizes the TransCon technology for the delivery of cytokines for cancer immunotherapy. Products The most well-known product of Ascendis Pharma A/S is TransCon Growth Hormone, a growth hormone therapy that has longer-lasting effects and only needs to be administered once a week for children with growth hormone deficiency. The company also has TransCon PTH and TransCon CNP in the endocrinology pipeline. In oncology, the company has developed TransCon IL-2, an interleukin-2 immunotherapy for cancer. Summary Ascendis Pharma A/S is an innovative biopharmaceutical company specializing in the development of therapies for chronic diseases. The company utilizes its proprietary technology platform, TransCon technology, to develop drugs that have longer-lasting effects and reduce the need for frequent doses. It focuses on endocrinology and oncology and follows an asset-based business model strategy by entering partnerships with established pharmaceutical companies. The most well-known product of Ascendis Pharma A/S is TransCon Growth Hormone. Ascendis Pharma A/S is one of the most popular companies on Eulerpool.

Debt Details

Understanding Ascendis Pharma A/S's Debt Structure

Ascendis Pharma A/S's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Ascendis Pharma A/S's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Ascendis Pharma A/S’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Ascendis Pharma A/S’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Ascendis Pharma A/S stock

Debt of Ascendis Pharma A/S is 871.41 M EUR in 2025.

Debt of Ascendis Pharma A/S changed from 856.62 M EUR to 871.41 M EUR, representing a 1.73% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Ascendis Pharma A/S since 2006 – with annual values, charts, and detailed analysis.

Debt's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Ascendis Pharma A/S historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Ascendis Pharma A/S

All Key Metrics — Ascendis Pharma A/S